DALLAS, June 18, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/ONTY
Oncothyreon Inc. (ONTY) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. ONTY's lead product candidate is Stimuvax, which is a cancer vaccine in phase III development for non-small cell lung cancer (NSCLC). ONTY has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany, for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates consists of cancer vaccines and small molecule candidates. The Company's wholly owned subsidiaries include ONTY Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.
Message Board Search for ONTY: http://www.boardcentral.com/boards/ONTY
In the report, the analyst notes:
"ONTY recently reported a net loss of $0.8 million or $0.03 per basic and diluted share for the quarter ended March 31, 2010, compared with a net loss of $2.5 million or $0.13 per basic and diluted share for the comparable period in 2009. The decrease in net loss is primarily the result of a decrease in fair value of warrant liability of $4.6 million, offset by an increase in net loss from operations.
"ONTY recently announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cancer (NSCLC), including the phase 3 START and INSPIRE trials. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees."
To read the entire report visit: www.microstockprofit.com/lp/ONTY
See what investors are saying about ONTY at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.